In8bio Inc (INAB)

Currency in USD
2.440
+0.030(+1.24%)
Closed·
After Hours
2.400-0.040(-1.64%)
·
INAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 11 days
Fair Value
Day's Range
2.3002.460
52 wk Range
2.05026.757
Key Statistics
Prev. Close
2.41
Open
2.42
Day's Range
2.3-2.46
52 wk Range
2.05-26.757
Volume
120.65K
Average Volume (3m)
211.35K
1-Year Change
-90.31%
Book Value / Share
5.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
107.700
Upside
+4,313.94%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

In8bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

In8bio Inc Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

Compare INAB to Peers and Sector

Metrics to compare
INAB
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.1x−0.5x
PEG Ratio
−0.010.020.00
Price/Book
0.6x3.0x2.6x
Price / LTM Sales
-9.4x3.2x
Upside (Analyst Target)
-151.9%41.4%
Fair Value Upside
Unlock9.3%6.0%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 107.700
(+4,313.94% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.07 / -0.0725
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

INAB Income Statement

People Also Watch

11.93
SRPT
-7.38%
1.23
KLTO
-3.15%
2.25
BMGL
+0.45%
0.069
HCTI
+25.78%
0.980
WINT
-3.92%

FAQ

What Stock Exchange Does In8bio Trade On?

In8bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for In8bio?

The stock symbol for In8bio is "INAB."

What Is the In8bio Market Cap?

As of today, In8bio market cap is 8.40M.

What Is In8bio's Earnings Per Share (TTM)?

The In8bio EPS (TTM) is -12.94.

When Is the Next In8bio Earnings Date?

In8bio will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is INAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has In8bio Stock Split?

In8bio has split 1 times.

How Many Employees Does In8bio Have?

In8bio has 18 employees.

What is the current trading status of In8bio (INAB)?

As of 27 Jul 2025, In8bio (INAB) is trading at a price of 2.44, with a previous close of 2.41. The stock has fluctuated within a day range of 2.30 to 2.46, while its 52-week range spans from 2.05 to 26.76.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.